Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Ketil André Camilio, Mengyu Wang, Brynjar Mauseth, Stein Waagene, Gunnar Kvalheim, Øystein Rekdal, Baldur Sveinbjørnsson, Gunhild M. MælandsmoBreast 2019 · DOI

Abstract

Our data demonstrate that LTX-315 is a promising combination partner with CAELYX® for the treatment of triple-negative breast cancer.

Introduction

Triple-negative breast cancer (TNBC) remains one of the most challenging oncology targets due to its aggressive nature and lack of standard hormonal or HER2-targeted receptors. Consequently, chemotherapy remains the primary treatment modality, though it is often insufficient. A major hurdle in TNBC is that tumors are frequently "immunologically cold," characterized by a lack of tumor-infiltrating lymphocytes (TILs). This exclusion prevents the immune system from recognizing and attacking the cancer, rendering even modern checkpoint inhibitors ineffective.

This study, published in Breast Cancer Research, investigates a novel therapeutic strategy: combining the oncolytic peptide LTX-315 with liposomal doxorubicin (CAELYX®). LTX-315 is a cationic peptide designed to physically disrupt cancer cell membranes and mitochondria, inducing immunogenic cell death (ICD). By acting as an "immune primer," LTX-315 aims to turn "cold" tumors "hot," facilitating robust T-cell infiltration and enhancing the efficacy of standard chemotherapy.

Methods

The researchers employed the 4T1 mammary fat pad model, a highly aggressive murine TNBC model that mimics stage IV human disease, including spontaneous lung metastasis. Experiments were conducted in syngeneic Balb/C mice to ensure an intact immune system for studying response dynamics.

The study utilized two primary experimental designs:

  1. Direct Combination Therapy: Established tumors were treated with intratumoral injections of LTX-315 (0.5 mg) and intravenous CAELYX® (8 mg/kg).
  2. Neoadjuvant Setting: To mimic clinical practice, the combination therapy was administered prior to the surgical excision of the primary tumor to evaluate its impact on relapse and metastatic spread.
Experimental timeline for the neoadjuvant study, showing cell inoculation, treatment windows, surgery, and subsequent imaging intervals.

Tumor progression and immune response were monitored using Bioluminescence Imaging (BLI) for tumor load, 7T MRI for internal necrosis visualization, and flow cytometry/immunohistochemistry to quantify immune cell infiltration.

Results

The combination of LTX-315 and CAELYX® demonstrated significant synergistic effects:

  • Complete Regression and Survival: In the combination group, 50% of the animals achieved complete tumor regression and remained tumor-free throughout the study. The median survival for the combination group reached 64.5 days, a substantial increase from the 25-day median survival observed in the control group.
  • Enhanced Immune Infiltration: While control tumors showed T-cell exclusion, the combination therapy successfully broke this barrier. CD4+ and CD8+ T-cells were observed infiltrating the viable tumor parenchyma.
  • Tumor Debulking: MRI and BLI confirmed massive internal necrosis and a rapid decrease in metabolic activity within the tumors following combination treatment.
  • Neoadjuvant Efficacy: In the surgical model, administering the combination therapy prior to excision resulted in a 60–97% increase in median survival compared to surgery alone or monotherapies. This suggests the treatment primes the immune system to target micro-metastases effectively.

Discussion

The study highlights the "flare" effect of LTX-315, which releases Danger-Associated Molecular Patterns (DAMPs) like ATP and HMGB1, signaling the innate immune system. When combined with doxorubicin, which further induces ICD and inhibits immunosuppressive myeloid-derived suppressor cells (MDSCs), the treatment reshapes the tumor microenvironment.

While these preclinical results are promising, limitations include the inherent differences between murine and human immune systems. Future work will focus on clinical translation, optimizing human dosing to balance efficacy with local toxicity, and further exploring the potential for "abscopal effects" on distant metastatic nodules.

Conclusion

LTX-315 acts as a powerful immune primer when combined with liposomal doxorubicin. By converting immunologically "cold" TNBC tumors into "hot" ones, this combination therapy demonstrates significant potential for improving long-term survival and preventing metastatic relapse.

Summary updated

Abstract

Our data demonstrate that LTX-315 is a promising combination partner with CAELYX® for the treatment of triple-negative breast cancer.
BibTeX
@inproceedings{camilio2019combining,
  author = {Ketil André Camilio and Mengyu Wang and Brynjar Mauseth and Stein Waagene and Gunnar Kvalheim and Øystein Rekdal and Baldur Sveinbjørnsson and Gunhild M. Mælandsmo},
  title = {{Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model}},
  booktitle = {Breast},
  year = {2019},
  doi = {10.1186/s13058-018-1092-x},
}
Figure